Mostrar el registro sencillo del ítem
dc.contributor.author | Frisoni, Giovanni B. | |
dc.contributor.author | Hansson, Oskar | |
dc.contributor.author | Nichols, Emma | |
dc.contributor.author | Garibotto, Valentina | |
dc.contributor.author | Schindler, Suzanne E. | |
dc.contributor.author | van der Flier, Wiesje M. | |
dc.contributor.author | Jessen, Frank | |
dc.contributor.author | Villain, Nicolas | |
dc.contributor.author | Arenaza-Urquijo, Eider M. | |
dc.contributor.author | Crivelli, Lucia | |
dc.contributor.author | Fortea, Juan | |
dc.contributor.author | Grinberg, Lea T. | |
dc.contributor.author | Ismail, Zahinoor | |
dc.contributor.author | Minoshima, Satoshi | |
dc.contributor.author | Ossenkoppele, Rik | |
dc.contributor.author | Zetterberg, Henrik | |
dc.contributor.author | Petersen, Ronald C. | |
dc.contributor.author | Dubois, Bruno | |
dc.date.accessioned | 2025-10-21T15:52:12Z | |
dc.date.available | 2025-10-21T15:52:12Z | |
dc.date.issued | 2025-09-22 | |
dc.identifier.citation | Frisoni GB, Hansson O, Nichols E, Garibotto V, Schindler SE, van der Flier WM, et al. New landscape of the diagnosis of Alzheimer’s disease. Lancet. 27 de septiembre de 2025;406(10510):1389-407 | es_ES |
dc.identifier.uri | https://doi.org/10.1016/S0140-6736(25)01294-2 | |
dc.identifier.uri | https://repositorio.fleni.org.ar/xmlui/handle/123456789/1417 | |
dc.description.abstract | Alzheimer's disease involves a drastic departure from the cognitive, functional, and behavioural trajectory of normal ageing, and is both a dreaded and highly prevalent cause of disability to individuals, and a leading source of health and social care expenditure for society. Before the advent of biomarkers, post-mortem examination was the only method available to establish a definitive diagnosis. In this first paper of the Series, we review state-of-the-art diagnostic practices and the typical patient journey in specialist settings, where clinicians engage in a differential diagnosis to establish whether Alzheimer's pathology (cerebral deposition of β-amyloid and hyperphosphorylated tau) is a contributor to cognitive impairment. Biomarkers indicating dysregulation of β-amyloid and tau homeostasis, measured with PET and cerebrospinal fluid analysis, allow a molecular-level diagnosis-a mandatory step in defining eligibility for the recently approved anti-amyloid treatments. We anticipate that easily accessible blood biomarkers, already available in some countries, will lead to a new diagnostic revolution and bring about major changes in health-care systems worldwide. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Elsevier | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.subject | Alzheimer Disease | es_ES |
dc.subject | Enfermedad de Alzheimer | es_ES |
dc.subject | Amyloid beta-Peptides | es_ES |
dc.subject | Péptidos beta-Amiloides | es_ES |
dc.subject | Biomarkers | es_ES |
dc.subject | Biomarcadores | es_ES |
dc.subject | Diagnosis, Differential | es_ES |
dc.subject | Diagnóstico Diferencial | es_ES |
dc.subject | Positron-Emission Tomography | es_ES |
dc.subject | Tomografía de Emisión de Positrones | es_ES |
dc.subject | tau Proteins | es_ES |
dc.subject | Proteínas tau | es_ES |
dc.title | New landscape of the diagnosis of Alzheimer's disease | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.type | info:eu-repo/semantics/publishedVersion | |
dc.description.fil | Fil: Crivelli, Lucía. Fleni. Departamento de Neurología. Servicio de Neurología Cognitiva, Neuropsicología y Neuropsiquiatría; Argentina. | |
dc.relation.ispartofVOLUME | 406 | |
dc.relation.ispartofNUMBER | 10510 | |
dc.relation.ispartofPAGINATION | 1389-1407 | |
dc.relation.ispartofCOUNTRY | Reino Unido | |
dc.relation.ispartofCITY | Londres | |
dc.relation.ispartofTITLE | Lancet | |
dc.relation.ispartofISSN | 1474-547X | |
dc.type.snrd | info:ar-repo/semantics/artículo | es_ES |